VIVA BIOTECH (01873) announced its interim results, with an adjusted net profit of 128 million yuan, a year-on-year decrease of 30.08%.

VIVA BIOTECH (01873) announced its interim results for the six months ended June 30, 2026, reporting revenues of 1.0065 billion yuan, a year-on-year increase of 20.99%; net profit of 100.9 million yuan, a year-on-year decrease of 32.1%; adjusted net profit under non-International Financial Reporting Standards of 128 million yuan, a year-on-year decrease of 30.08%; and basic earnings per share of 0.04 yuan. In the first half of 2026, the group's net profit was 100.9 million yuan, and the adjusted net profit under non-International Financial Reporting Standards was 128 million yuan, both decreasing compared to the same period last year. This was mainly attributed to the decline in contributions from investment income during the reporting period, adverse impacts from foreign exchange rate fluctuations, and increased R&D expenses associated with the development of new businesses. However, the group remains confident that as the short-term suppressive factors are gradually mitigated, taking into account the sustained improvement in the CRO business and the potential for the commercialization of the two products from Langhua CDMO, along with the potential opportunities arising from the investment incubation company exiting, the group's net profit will still maintain an optimistic growth trend in the medium to long term.